The activation of nitric oxide (NO) production is an analgesic mechanism shared by drugs such as morphine and diclofenac. Therefore, the controlled release of low amounts of NO seems to be a promising analgesic approach. In the present study, the antinociceptive effect of the ruthenium NO donor [Ru(bpy) 2 (NO)SO 3 ](PF 6 ) (complex I) was investigated. It was observed that complex I inhibited in a dose (0.3-10 mg/kg)-dependent manner the acetic acid-induced writhing response. At the dose of 1 mg/kg, complex I inhibited the phenyl-p-benzoquinone-induced writhing response and formalin-and complete Freund's adjuvant-induced licking and flinch responses. Additionally, complex I also inhibited transient receptor potential cation channel subfamily V member 1 (TRPV1)-dependent overt pain-like behavior induced by capsaicin. Complex I also inhibited the carrageenin-induced mechanical hyperalgesia and increase of myeloperoxidase activity (MPO) in paw skin samples. The inhibitory effect of complex I in the carrageenin-induced hyperalgesia, MPO activity and formalin was prevented by the treatment with ODQ, KT5823 and glybenclamide, indicating that complex I inhibits inflammatory hyperalgesia by activating the cGMP/ PKG/ATP-sensitive potassium channel signaling pathway. The present study demonstrates the efficacy of a novel ruthenium NO donor and its analgesic mechanisms.
Introduction
The animal models evaluate two main symptoms of pain: i) overt nociception/overt pain-like behavior or ii) hyperalgesia and allodynia. In overt nociception/overt pain-like behavior, an inflammatory stimulus induces a declared behavior such as paw flinch or licking and abdominal contortions (writhing) without further mechanical or thermal external stimuli. This declared behavior occurs because the overt nociceptive stimuli activate or induce fast production of endogenous mediators that activate the nociceptors (Collier et al., 1968; Dubuisson and Dennis, 1977; Pavao-de-Souza et al., 2012; Ribeiro et al., 2000; .
Hyperalgesia is defined as an increase of pain sensation caused by a stimulus that normally induces pain and allodynia as pain due to a stimulus that does not normally provoke pain. Both result from the sensitization of nociceptors in which, for instance, inflammatory mediators activate second messenger pathways resulting in the lowering of the nociceptor threshold and increasing neuronal membrane excitability (Pavao-de-Souza et al., 2012; Verri et al., 2006) .
Experimentally, peripheral pharmacological control of inflammatory hyperalgesia is based on two strategies. The first is the prevention of nociceptor sensitization, which can be achieved with non-steroidal anti-inflammatory (aspirin-like) drugs that inhibit prostaglandin synthesis (Ferreira, 1972) . The second strategy is the direct blockade of the current nociceptor sensitization, which can be achieved by the use Pharmacology, Biochemistry and Behavior 105 (2013) [157] [158] [159] [160] [161] [162] [163] [164] [165] Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CFA, complete Freund's adjuvant; cGMP, cyclic monophosphate guanosine; GLY, glybenclamide; HTAB, hexadecyltrimethylammonium bromide; KT5823, 2, 3, 9,10, 11, 12-hexahydro-10R-methoxy-2, 9-dimethyl-1-oxo-9S, 12R-epoxy-1H-diindolo [1, 2, 3-fg:3′, 2′, 1′-kl] pyrrolo [3, 4-i] [1, 6]benzodiazocine-10-carboxylic acid, methyl este; MPO, myeloperoxidase; NO, nitric oxide; NOS, nitric oxide synthase; eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase, nNOS, neuronal nitric oxide synthase; NSAIDS, nonsteroidal anti-inflammatory drugs; ODQ, 1H- [1, 2, 4] oxadiazolo [4,3-a] quinoxalin-1-one; PBQ, phenyl-p-benzoquinone; PGE2, prostaglandin E2; PKG, cGMP-dependent protein kinase; TRP channels, transient receptor potential channels; TRPV1 channel, transient receptor potential vanilloid 1.of peripheral opioids, analgesics (e.g. dipirone) and NO donors (Cunha et al., 2010; Ferreira et al., 1991b; Lorenzetti and Ferreira, 1985; Sachs et al., 2004) . These drugs are able to inhibit the already established hyperalgesia induced by PGE 2 (Cunha et al., 2010 Ferreira et al., 1991a; Lorenzetti and Ferreira, 1985; Sachs et al., 2004) . Moreover, several studies have demonstrated that the antinociceptive mechanism of these drugs depends on the activation of the L-arginine/NO/guanosine 3, 5-cyclic monophosphate (cGMP)/protein kinase G (PKG)/ATP-sensitive potassium channel pathway (Cunha et al., 2010 Ferreira et al., 1991a; Mizokami et al., 2012; Napimoga et al., 2008; Sachs et al., 2004; Santodomingo-Garzon et al., 2006; Vivancos et al., 2003) . However, the control of inflammatory pain is still a major challenge because of the deleterious side effects attributed to the prolonged use of NSAIDs and opioids, their ineffectiveness in some cases and receptor desensitization in the case of opioids.
Nitric oxide is produced in mammalian cells from L-arginine and oxygen by three isoforms of the enzyme NO synthase (NOS): neuronal (nNOS or type I), inducible (iNOS or type II) and endothelial (eNOS or type III) (Alderton et al., 2001; Moncada et al., 1991 ). An important difference between the isoforms of NOS is that the constitutive type produces low NO concentrations in the nmol L −1 range, while the inducible form produces NO in the μmol L −1 range (Pagliaro, 2003) . Accordingly, nitric oxide plays an important role in a variety of physiological functions, such as blood pressure control (Moncada and Higgs, 1993) , neurotransmission (Bredt et al., 1990; Garthwaite, 1991) , immunological and inflammatory responses (Hibbs et al., 1988; Rees et al., 1989; Silva et al., 2007) and antioxidant action (McCleverty, 2004; Wink and Mitchell, 2003) . These effects are quite dependent on the local NO bioavailability and concentration (Wink and Mitchell, 1998) . Therefore, intense efforts have been devoted to develop new compounds that deliver NO efficiently and in a controlled manner (Tfouni et al., 2012) . In models of nociception, it is consensus that NO activates the cGMP/PKG/ATP-sensitive potassium channel signaling pathway (Kawabata et al., 1994; Li and Qi, 2010; Sousa and Prado, 2001; Tegeder et al., 2002; Vivancos et al., 2003) , which is also the signaling pathway activated by the peripheral action of opioids (Cunha et al., 2010 . Therefore, NO donors could be used to achieve similar effects as of peripheral opioids without the side effects related to opioid receptor activation. In this context, our group has synthesized a nitrosyl ruthenium complex that donates NO, [Ru (bpy) 2 (NO)SO 3 ](PF 6 ) here named as complex I. We have previously demonstrated that mice treated with complex I are more resistant to paracoccidioidomycosis infection, which was observed as prolonged survival with reduced leukocyte recruitment and TNFα production in the lung and liver as well as increased production of the anti-inflammatory cytokine IL-10 (Pavanelli et al., 2011) . Furthermore, the complex I presents additional biological activities against several diseases such as in vitro and in vivo trypanocidal activities and beneficial effects in a model of ischemia/ reperfusion in the brain (Campelo et al., 2012) .
Some interesting characteristics of ruthenium NO donors are the release of NO through electrochemical, photochemical and chemical processes . The rate constant for the NO release induced by thiols is pH-dependent and increases by raising the pH, due to the acid-base equilibrium of thiol group of the cysteine residue . In this respect, ruthenium compounds could be useful as delivery or scavenging agents for molecules that have a crucial role in physiology (Tfouni et al., 2012) . Moreover, NO-donors are of great interest due to their outstanding properties, such as the low cytotoxicity against host cells, water solubility, stability to air oxidation and tailoring reactivity possibilities of the coordinated NO Lopes et al., 1998; Toledo et al., 2002; Tfouni et al., 2012) .
Considering the information above, in the present study we investigated the mechanism involved in the antinociceptive effect of [Ru(bpy) 2 (NO)SO 3 ](PF 6 ) in models of overt pain-like behavior and in carrageenin-induced mechanical inflammatory hyperalgesia. The role of cGMP/PKG/ATP-sensitive potassium channel signaling pathway was also investigated.
Material and methods

Animals
Male Swiss mice (25-30 g) from the Universidade Estadual de Londrina, Paraná, Brazil, were used in this study. Mice were housed in standard clear plastic cages with free access to food and water and a light/dark cycle of 12:12 h and kept at 21°C. Different investigators prepared the solutions, treated the mice, injected the stimulus and quantified the nociceptive behaviors. All behavioral testing was performed between 9 am and 5 pm in a temperature-controlled room. Animal care and handling procedures were in accordance with the International Association for the Study of Pain (IASP) guidelines and with the approval of the Ethics Committee of the Universidade Estadual de Londrina. All efforts were made to minimize the number of animals used and their suffering. It is noteworthy that different experimenters prepared the solutions, made the administrations and performed the evaluation of pain-like behavior.
Drugs
The following materials were obtained from the sources indicated: acetic acid from Mallinckrodt Baker, S.A. (Mexico City, Mexico); glybenclamide, capsaicin, KT5823 (2,3,9,10,11,12-hexahydro-10R-methoxy-2,9-dimethyl-1-oxo-9S,12R-epoxy-1diindolo Louis, MO), formalin from Merck (Darmstadt, Germany). The selected doses of drugs were chosen based on pilot studies and previous data of our laboratory. We detected that the doses of drugs used do not alter the nociceptive response per se, and inhibit the respective standard stimulus (Cunha et al., 2010; Mizokami et al., 2012; Vale et al., 2007; Valerio et al., 2009; Verri et al., 2008) .
Synthesis of ruthenium NO donor [Ru(bpy) 2 (NO)SO 3 ](PF 6 ) (complex I)
The ruthenium NO donor [Ru(bpy) 2 (NO)SO 3 ](PF 6 ) namely complex I was synthesized and characterized as we previously described . Elemental analysis of hydrogen, carbon, and nitrogen was carried out using an EA 1110 CHNS-O CE instrument. Analysis of ruthenium was performed as described elsewhere (Clarke, 1978) , using a Polarized Zeeman atomic absorption spectrophotometer, Hitachi (model Z-8100), with a Hitachi Hollow Cathode Lamp, 12 mA, and k=349.9 nm. UV visible measurements were performed in a 1.0 cm quartz cell in a Hewlett-Packard diode array model 8452A spectrophotometer. IR spectra were recorded with a Bomem FTIR, model MB-102, spectrophotometer in the 400-4000 cm −1 range, with the sample supported in potassium bromide pellets. A polarographic analyzer/stripping voltammeter model 264A from Princeton Applied Research attached to a microcomputer and employing Microquimica Eletrochemical software was used for the electrochemical measurements. The electrochemical cell used was a conventional three-electrode type with an aqueous saturated calomel electrode as a reference electrode and a glassy carbon and platinum wire as working and auxiliary electrodes, respectively (Pavanelli et al., 2011) .
Writhing response tests
The PBQ (Emele and Shanaman, 1967) and acetic acid (Collier et al., 1968) induced writhing models were performed as previously described (Pavao-de-Souza et al., 2012). Mice were pretreated with nitric oxide donor, complex I (0.3-10.0 mg or 1.0 mg/kg/s.c./saline), 40 min before i.p. stimulus with PBQ diluted in DMSO 2%/saline (1890 μg/kg), acetic acid (0.8% v/v, saline, 10 mL/kg) or vehicle. After all treatments, each mouse was placed in a large glass cylinder and the intensity of nociceptive behavior was quantified by counting the total number of writhes occurring between 0 and 20 min after stimulus injection. The writhing response consists of a contraction of the abdominal muscle together with a stretching of hind limbs. The intensity of the writhing response was expressed as the cumulative writhing score over 20 min.
CFA test
The number of paw flinches and time spent licking the paw were determined between 0 and 30 min after intraplantar injection of 10 μL of complete Freund's adjuvant (CFA). Results were expressed by the total number of flinches and licks performed during 30 min ).
Capsaicin test
The procedure used was similar to that described previously (Otuki et al., 2005) . After an adaptation period, 20 μL of capsaicin (5.2 nmol/paw prepared in saline) was injected intraplantar (i.pl.) under the surface of the right hind paw. Animals were observed individually for 5 min following capsaicin injection. The amount of time spent licking and flinches in the injected paw was considered as indicative of nociception.
Formalin Test
The number of paw flinches and time spent licking the paw were determined between 0 and 30 min after intraplantar injection of 25 μL of formalin 1.5%, as previously described. The period was divided in intervals of 5 min and clearly demonstrated the presence of the first and second phases, which are characteristic of the method (Dubuisson and Dennis, 1977) .
Mechanical nociceptive paw test
Mechanical hyperalgesia was tested in mice as previously reported . In a quiet room, mice were placed in acrylic cages (12× 10 ×17 cm) with wire grid floors 15-30 min before the start of testing. The test consisted of evoking a hind paw flexion reflex with a handheld force transducer (electronic anesthesiometer, IITC Life Science, Woodland Hills, CA) adapted with a 0.5 mm 2 polypropylene tip. The investigator was trained to apply the tip perpendicularly to the central area of the plantar hind paw with a gradual increase in pressure. The gradual increase in pressure was manually performed in blinded experiments. The upper limit pressure was 15 g. The end-point was characterized by the removal of the paw followed by clear flinching movements. After paw withdrawal, the intensity of the pressure was automatically recorded, and the final value for the response was obtained by averaging three measurements. The animals were tested before and after treatments. The results are expressed by delta (Δ) withdrawal threshold (in g) calculated by subtracting the zero-time mean measurements from the mean measurements 1.3 and 5 h after stimulus. Withdrawal threshold was 9.1 ± 0.4 g (mean± SEM; n = 30) before injection of the hyperalgesic agents (e.g., carrageenin).
Myeloperoxidase (MPO) assay
Neutrophil migration to the hind paw plantar tissues of mice was evaluated using a myeloperoxidase (MPO) kinetic-colorimetric assay as previously described (Bradley et al., 1982; Casagrande et al., 2006) . Samples of subcutaneous plantar tissue were collected in 50 mM K 2 HPO 4 buffer (pH 6.0) containing 0.5% hexadecyltrimethylammonium bromide (HTAB) and kept at −80°C until use. Samples were homogenized using a Polytron (PT3100), centrifuged at 16,100 g for 4 min, and the resulting supernatant was assayed for MPO activity spectrophotometrically at 450 nm (Spectra max), with three readings in 1 min. The MPO activity of samples was compared to a standard curve of neutrophils. Briefly, 15 μL of sample was mixed with 200 μL of 50 mM phosphate buffer, pH 6.0, containing 0.167 mg/mL O-dianisidine dihydrochloride and 0.0005% hydrogen peroxide. The results are presented as MPO activity (number of neutrophils × 10 4 per mg of tissue).
Measurement of Motor Performance
In order to discard possible nonspecific muscle relaxant or sedative effects of complex I, mice motor performance was evaluated using the rota-rod test Valério et al., 2007) . The apparatus consisted of a bar with a diameter of 2.5 cm, subdivided into six compartments by disks 25 cm in diameter (Ugo Basile, model 7600). The bar rotated at a constant speed of 22 rpm. The animals were selected 24 h previously by eliminating those mice that did not remain on the bar for two consecutive periods of 120 s. Animals were treated with vehicle (saline) or complex I (3 mg/kg, s.c.), and testing was performed 1, 3, and 5 h after treatment. The cutoff time used was 120 s.
Acute toxicity
To investigate the potential acute toxicity caused by complex I, the mice received a single subcutaneous dose of complex I (3 mg/kg) or vehicle (saline). Five hours after the treatment, the animals were anesthetized prior to blood collection by heart puncture into heparin containing tubes. Plasma was obtained by centrifugation at 0.4 rcf for 10 min. Plasma aspartate (AST) and alanine (ALT) aminotransferases activities were used as biochemical markers for early acute hepatic damage. These assays were performed using a diagnostic kit from Labtest (Lagoa Santa, Minas Gerais, Brazil) .
Statistical analysis
Results are presented as means± SEM of measurements made on 6 mice in each group. Two-way analysis of variance (ANOVA) was used to compare the groups and doses at all times (curves). The analyzed factors were treatments, time and time versus treatment interaction. When there was a significant time versus treatment interaction, oneway ANOVA followed by Tukey's t-test was performed for each time. On the other hand, when the nociceptive responses were presented as total writhing within 20 min or at indicated time period, the differences between responses were evaluated by one-way ANOVA followed by Tukey's t-test. Statistical differences were considered to be significant at Pb 0.05.
Results
Complex I inhibits acetic acid-and phenyl-p-benzoquinone (PBQ)-induced writhing response
In the first series of experiments, it was addressed whether the complex I inhibits writhing response induced by acetic acid or PBQ. Mice were treated with 0.3-10 mg/kg or 1 mg/kg (s.c.) of complex I 40 min before acetic acid (Fig. 1A) or PBQ (Fig. 1B) injection, respectively. Although there was no statistical difference among the doses of complex I. The ruthenium NO donor inhibited in a dose-dependent profile the acetic acid writhing (Fig. 1A) . The dose of 0.3 mg/kg of complex I did not inhibit significantly the writhing response. On the other hand, the doses of 1-10 mg/kg inhibited the writhing response significantly without statistical differences among them (Fig. 1A) . Therefore, the dose of 1 mg/kg of title complex was selected for the next experiments on overt pain-like behavior. Complex I also inhibited the PBQ-induced writhing response.
Complex I inhibits complete Freund's adjuvant (CFA)-induced overt pain-like behavior
Mice were treated with complex I 40 min before CFA (10 μL) administration. The time spent licking the paw ( Fig. 2A) and the total number of paw flinches (Fig. 2B) were evaluated for over 30 min. The dose of 1 mg/kg of ruthenium NO donor inhibited CFA-induced overt painlike significantly (Fig. 2) . 
Complex I inhibits capsaicin-induced overt pain-like behavior
Mice were treated with complex I 40 min before capsaicin (5.2 nmol, 20 μL/paw) administration. The time spent licking the paw (Fig. 3A) and the total number of paw flinches (Fig. 3B) were evaluated for over 5 min. The dose of 1 mg/kg of ruthenium NO donor inhibited capsaicin-induced overt pain-like significantly (Fig. 3) .
Complex I inhibits formalin-induced overt pain-like behavior
Mice were treated with complex I 40 min before formalin (1.5%, 25 μL/paw) administration. The time spent licking the paw (Fig. 4A ) and the total number of paw flinches (Fig. 4B) were evaluated during 30 min. The dose of 1 mg/kg of complex I inhibited the first and second phases of formalin-induced overt pain-like behavior with a more pronounced effect in the nociception of the second phase of the test, which was abolished (Fig. 4). 3.5. Complex I inhibits formalin-induced overt pain-like behavior by activating the GMPc/PKG/KATP signaling pathway Mice were treated with ODQ (0.3 mg/kg, i.p., 30 min), KT5823 (0.5 μg/animal, i.p., 5 min) or glybenclamide (Gly; 0.3 mg/kg, p.o., 45 min) ( Fig. 5A-B ; C-D; and E-F; respectively) before complex I (1 mg/kg) or vehicle (Saline) treatment, and after an additional time of 40 min mice received the formalin (1.5%, 25 μL/paw) stimulus. The time spent licking the paw (Fig. 7A, C and E) and the total number of paw flinches (Fig. 5B, D and F) were evaluated during 30 min. All inhibitors (ODQ, KT5823 and glybenclamide) reversed complex I inhibition of formalin-induce overt pain-like behavior in the first and second phases of the test. Thus, the inhibition formalin-induced overt pain-like behavior by complex I depends on the activation of cGMP/PKG/ATP-sensitive potassium channel signaling pathway. The treatment with ODQ, KT5823 or glybenclamide did not present effect per se (data not shown).
Complex I inhibits carrageenin-induced mechanical hyperalgesia and neutrophil recruitment in a dose-dependent manner
Mice were treated with complex I (0.3-3 mg/kg, s.c.) or vehicle (saline) 40 min before carrageenin (100 μg/paw) stimulus, and the intensity of mechanical hyperalgesia (Fig. 6A) was evaluated after 1, 3 and 5 h. Afterwards (5 h), animals were sacrificed and samples of the subcutaneous plantar tissue were collected for myeloperoxidase (MPO) activity determination (Fig. 6B) . The dose of 0.3 mg/kg of complex I did not inhibit carrageenin-induced mechanical hyperalgesia (Fig. 6A) . On the other hand, the dose of 1 mg/kg inhibited at 3 h, and the dose of 3.0 mg/kg inhibited at 1, 3, and 5 h carrageenin-induced mechanical hyperalgesia (Fig. 6A) . Only the dose of 3.0 mg/kg of ruthenium NO donor inhibited the carrageenin-induced neutrophil recruitment to the paw skin as determined by MPO assay (Fig. 6B) . Based on the results of Fig. 6 , the dose of 3 mg/kg of complex I was selected for next experiments.
3.7. Complex I inhibits carrageenin-induced mechanical hyperalgesia and neutrophil recruitment by activating the cGMP/PKG/ATP-sensitive potassium channel pathway Mice were treated with ODQ (0.3 mg/kg, i.p., 30 min), KT5823 (0.5 μg/animal, i.p., 5 min) or glybenclamide (Gly; 0.3 mg/kg, p.o., 45 min) ( Fig. 7A-B ; C-D; and E-F; respectively) before complex I (3 mg/kg) or vehicle (Saline) treatment, and after an additional time of 40 min mice received the carrageenin (100 μg/paw) stimulus. The intensity of mechanical hyperalgesia was evaluated 1, 3 and 5 h after inflammatory stimulus administration (Fig. 7A, C and E) . Subsequently (5 h), the animals were sacrificed and subcutaneous plantar tissue was collected for MPO activity determination (Fig. 7B, D and F) . Complex I significantly inhibited carrageenin-induced mechanical hyperalgesia and neutrophil recruitment and these effects of ruthenium NO donor were prevented by the ODQ (Fig. 7A-B) , KT5823 (Fig. 7C-D) and glybenclamide ( Fig. 7E-F) treatments. Thus, the inhibition of mechanical hyperalgesia and neutrophil recruitment by complex I depends on the activation of cGMP/PKG/ATP-sensitive potassium channel signaling pathway. The treatment with ODQ, KT5823 or glybenclamide did not present effect per se (data not shown). 
Discussion
Nitric oxide (NO) is an intriguing molecule. It mediates many pathophysiological processes in which it has complex roles. Evidence suggests that NO may both induce and reduce pain. In the present study, it was investigated the analgesic effect of the ruthenium NO donor, [Ru(bpy) 2 (NO)SO 3 ](PF 6 ) (complex I), which inhibited the overt painlike behavior induced by acetic acid, phenyl-p-benzoquinone, complete Freund's adjuvant (CFA), formalin and capsaicin (Transient receptor potential cation channel subfamily V member 1 [TRPV1] agonist). Complex I also inhibited the overt pain-like behavior, mechanical hyperalgesia and neutrophil recruitment (myeloperoxidase [MPO] activity) in a guanylate cyclase, protein kinase G (PKG), and ATP-sensitive potassium channel-dependent manner.
Some drugs under clinical use present analgesic effects by activating the NO/cGMP/PKG/ATP-sensitive potassium channel signaling pathway reducing the nociceptive information transmission (Cunha et al., 2010; Sachs et al., 2004; Tonussi and Ferreira, 1994) . This group of drugs includes diclofenac and morphine (Cunha et al., 2010 Tonussi and Ferreira, 1994) . The analgesic effect of diclofenac depends on NO signaling (Tonussi and Ferreira, 1994) and inhibition of cyclooxygenase. This last mechanism gives its classification as non-steroidal antiinflammatory drug and side effects such as gastric and intestinal ulcers (Beck et al., 1990) . Morphine is an opioid analgesic that is effective in the majority of painful conditions. The peripheral mechanism of action of morphine relays in the opioid-receptor dependent activation of the above mentioned NO signaling pathway (Cunha et al., 2010 . However, its use is limited by side effects and opioid receptor desensitization that increases the dose need to obtain analgesia in chronic use (Carvalho et al., 2011; Devulder et al., 2009) , and raising the need of further drug options. Therefore, the activation of NO signaling pathway without the inhibition of cyclooxygenase or bypassing the opioid receptors would induce analgesia with reduced side effects.
In this sense, the delivery of NO using ruthenium NO donors could represent a successful analgesic strategy. There is a wide range of metal complexes that have biological activities and applications for diseases, such as cancer (Clarke et al., 1999; Dyson and Sava, 2006; Levina et al., 2009 ), cardiovascular problems (Bates et al., 1991) , arthritis (Forestier, 1935) , and parasitosis (Navarro, 2009) , and some of these complexes are commercially available (Tfouni et al., 2012) . In fact, the present results demonstrate the applicability of the novel ruthenium NO donor [Ru(bpy) 2 (NO)SO 3 ](PF 6 ) as an analgesic in models of overt pain-like behavior and mechanical hyperalgesia. The effect of complex I was dose-dependent indicating that the level of analgesia can be controlled according to the need. Furthermore, it was observed that complex I induced analgesia by activating the cGMP/PKG/ATP-sensitive potassium channel pathway (present data) similarly to morphine and diclofenac (Cunha et al., 2010 Tonussi and Ferreira, 1994) . In agreement with this mechanism, other ruthenium NO donors induce vasorelaxant effects in a soluble guanylate cyclase-and potassium channels-dependent manner (Lunardi et al., 2007; Pereira et al., 2011) . Furthermore, we speculate that the activation of the cGMP/ PKG/ATP-sensitive potassium channel pathway by complex I is a neuronal events as for morphine, which is also consistent with the inhibition of the first phase of formalin test described as a neuronal phase (Dubuisson and Dennis, 1977; present data) . In agreement with intracellular delivery of NO by complex I, this NO donor induces the relaxation of rabbit corpus cavernosum and aortic vascular endothelium by activating intracellular cGMP production since extracellular NO scavengers did not affect the relaxation induced by complex I (Cerqueira et al., 2008) . Complex I also inhibited the abdominal contortions induced by acetic acid and PBQ. This is consistent with the inhibition of zymosan-induced abdominal contortions by sildenafil by activating NO/cGMP/ATP sensitive potassium channels (Vale et al., 2007) . Therefore, the abdominal contortions behavioral response is susceptible to NO/cGMP/ATP sensitive potassium channels analgesic signaling pathway.
The treatment with complex I also increases the survival of mice in a model of Paracoccidioides brasiliensis infection with increased IL-10 levels while diminishing TNFα production. These results might be related to the microbicidal effect of NO released by this compound, which results in reduced microbial counts and reduced inflammation (Pavanelli et al., 2011) . This might be of importance in the context of pain during infection in which analgesics with anti-inflammatory effects may have a deleterious side effect of facilitating infection spreading by reducing the inflammatory response, and as demonstrated in P. brasiliensis infection model, treatment with complex I would not impair the host response (Pavanelli et al., 2011) . Furthermore, NO inhibits neutrophil recruitment by activating the cGMP/ PKG/ATP sensitive potassium channels signaling pathway (PaulaNeto et al., 2011) . These data corroborate the fact that complex I reduced the recruitment of inflammatory cells to the lung and liver tissue induced by P. brasiliensis infection (Pavanelli et al., 2011 ) and the present finding that complex I inhibited carrageenin-induced neutrophil recruitment to the paw skin as determined by the myeloperoxidase activity. The neutrophils recruited to the inflammatory foci contribute to pain by further producing nociceptive molecules such as prostaglandin E 2 and leukotriene B 4 Guerrero et al., 2008; Verri et al., 2009) . Therefore, inhibition of neutrophil recruitment by complex I might also be a contributing mechanism to its analgesic activity.
In addition to NO delivery, ruthenium is a molecule used to form complexes with varied activities. For instance, there is evidence that ruthenium complexes form non-selective TRP inhibitors as observed for ruthenium red (Liang et al., 2011) . In this sense, it was observed that complex I inhibited capsaicin-induced overt pain-like behavior, indicating the blockade of TRPV1-induced nociception as an analgesic mechanism of complex I (Caterina et al., 1997) . This effect seems to be NO-independent and ruthenium-dependent since ruthenium is the common feature between ruthenium red (does not present NO in its structure) and complex I. Furthermore, TRPV1 channels had been implicated in the nociception in some of the models tested in the present study including formalin, CFA and carrageenin (Kanai et al., 2006) , suggesting that blocked of TRPV1 may be an additional underlying analgesic mechanism of complex I.
Corroborating the potential applicability of ruthenium NO donor complexes, they present low cytotoxicity (Tfouni et al., 2012) . Herein, we observed that the treatment with complex I at an analgesic dose (3 mg/kg) did not alter the response in the rota-rod test within 5 h (time of carrageenin test), indicating that there was no motor impairment, muscle relaxing or acute toxicity in mice. Furthermore, there was no alteration in AST (aspartate aminotransferase) and ALT (alanine aminotransferase) plasma levels by treatment with complex I, indicating no acute liver damage (data not shown).
Concluding, this is the first study to demonstrate that [Ru(bpy) 2 (NO) SO 3 ](PF 6 ) induces analgesia by blocking TRPV1 agonist-induced nociception and activating the cGMP/PKG/ATP-sensitive potassium channel pathway. [Ru(bpy) 2 (NO)SO 3 ](PF 6 ) (complex I) inhibits carrageenin-induced mechanical hyperalgesia and neutrophil recruitment by activating the cGMP/PKG/ATP-sensitive potassium channel pathway. Mice received ODQ (0.3 mg/kg, i.p., 30 min), KT5823 (0.5 μg/animal, i.p., 5 min) or glybenclamide (Gly; 0.3 mg/kg, p.o., 45 min) (panels A-B; C-D; E-F; respectively) before of complex I (3 mg/kg,) or vehicle (saline -indicated as zero in panels B, D and F) subcutaneous treatment, and after an additional 40 min the mice received the carrageenin (100 μg/paw) intraplantar (i.pl.) stimulus. The intensity of mechanical hyperalgesia was evaluated 1, 3 and 5 h after inflammatory stimulus administration with electronic pressure-meter (panels A, C and E). The samples of subcutaneous plantar tissue were collected 5 h after carrageenin stimulus and the myeloperoxidase (MPO) activity was determined (panels B, D and F). Results are presented as means± SEM of 6 mice per group, and are representative of 2 separate experiments. ⁎ Pb 0.05 compared to the saline group (panels A-F); # Pb 0.05 compared the carrageenin group (panels A-F); ⁎⁎ Pb 0.05 compared to complex I group (panels A-F) (one-way ANOVA followed by Tukey's test).
